[go: up one dir, main page]

WO2006037994A3 - Egfr mutations altering the response to erbb receptor drugs - Google Patents

Egfr mutations altering the response to erbb receptor drugs Download PDF

Info

Publication number
WO2006037994A3
WO2006037994A3 PCT/GB2005/003814 GB2005003814W WO2006037994A3 WO 2006037994 A3 WO2006037994 A3 WO 2006037994A3 GB 2005003814 W GB2005003814 W GB 2005003814W WO 2006037994 A3 WO2006037994 A3 WO 2006037994A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb receptor
response
egfr mutations
mutations altering
egfr
Prior art date
Application number
PCT/GB2005/003814
Other languages
French (fr)
Other versions
WO2006037994A2 (en
Inventor
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0422158A external-priority patent/GB0422158D0/en
Priority claimed from GB0508493A external-priority patent/GB0508493D0/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Gillian Ellison, Ruth Eleanor March, Alan Wookey filed Critical Astrazeneca Ab
Publication of WO2006037994A2 publication Critical patent/WO2006037994A2/en
Publication of WO2006037994A3 publication Critical patent/WO2006037994A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a method for predicting the likelihood that a patient who is a candidate for treatment with an erbB receptor drug will respond to said treatment, comprising determining the sequence of EGFR in a tumour sample from the patient, whereby to predict an increased likelihood of response to the erbB receptor drug. In particular, determining the sequence of EGFR at any of the following positions as defined in SEQ ID NO: 1: position 2308 is A; position 2348 is T; position 2588 is A; or position 2689 is A or at any of the following positions as defined in SEQ ID NO: 2: position 770 is asparagine; 783 is isoleucine; position 863 is aspartic acid; or position 897 is isoleucine.
PCT/GB2005/003814 2004-10-06 2005-10-04 Egfr mutations altering the response to erbb receptor drugs WO2006037994A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0422158.6 2004-10-06
GB0422158A GB0422158D0 (en) 2004-10-06 2004-10-06 Method
GB0508493A GB0508493D0 (en) 2005-04-27 2005-04-27 Method
GB0508493.4 2005-04-27

Publications (2)

Publication Number Publication Date
WO2006037994A2 WO2006037994A2 (en) 2006-04-13
WO2006037994A3 true WO2006037994A3 (en) 2006-06-08

Family

ID=35453337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003814 WO2006037994A2 (en) 2004-10-06 2005-10-04 Egfr mutations altering the response to erbb receptor drugs

Country Status (2)

Country Link
TW (1) TW200617396A (en)
WO (1) WO2006037994A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506670D0 (en) * 2005-04-01 2005-05-11 Astrazeneca Ab Method
CN106755297A (en) * 2016-11-15 2017-05-31 上海派森诺医学检验所有限公司 One group is based on primer sets that ARMS fluorescence quantitative PCR detection EGFR genes T790M is mutated and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094357A2 (en) * 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094357A2 (en) * 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
GAZDAR A F ET AL: "Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 10, no. 10, October 2004 (2004-10-01), pages 481 - 486, XP004586557, ISSN: 1471-4914 *
HUANG SHIU-FENG ET AL: "High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 DEC 2004, vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8195 - 8203, XP002369911, ISSN: 1078-0432 *
KOSAKA TAKAYUKI ET AL: "Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.", CANCER RESEARCH. 15 DEC 2004, vol. 64, no. 24, 15 December 2004 (2004-12-15), pages 8919 - 8923, XP002369912, ISSN: 0008-5472 *
LYNCH THOMAS J ET AL: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.", THE NEW ENGLAND JOURNAL OF MEDICINE. 20 MAY 2004, vol. 350, no. 21, 20 May 2004 (2004-05-20), pages 2129 - 2139, XP002359960, ISSN: 1533-4406 *
MARCHETTI ANTONIO ET AL: "EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 FEB 2005, vol. 23, no. 4, 1 February 2005 (2005-02-01), pages 857 - 865, XP002369910, ISSN: 0732-183X *
PAEZ J GUILLERMO ET AL: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.", SCIENCE. 4 JUN 2004, vol. 304, no. 5676, 4 June 2004 (2004-06-04), pages 1497 - 1500, XP002359959, ISSN: 1095-9203 *
PAO W ET AL: "EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13306 - 13311, XP002334314, ISSN: 0027-8424 *
PAO WILLIAM ET AL: "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.", PLOS MEDICINE / PUBLIC LIBRARY OF SCIENCE. MAR 2005, vol. 2, no. 3, March 2005 (2005-03-01), pages e73, XP002359961, ISSN: 1549-1676 *
ROSELL ET AL: "Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 50, no. 1, October 2005 (2005-10-01), pages 25 - 33, XP005106172, ISSN: 0169-5002 *
TARON MIGUEL ET AL: "Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 AUG 2005, vol. 11, no. 16, 15 August 2005 (2005-08-15), pages 5878 - 5885, XP002369908, ISSN: 1078-0432 *
TOKUMO MASAKI ET AL: "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 FEB 2005, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1167 - 1173, XP002369909, ISSN: 1078-0432 *
TOMIZAWA YOSHIO ET AL: "Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 OCT 2005, vol. 11, no. 19 Pt 1, 1 October 2005 (2005-10-01), pages 6816 - 6822, XP002369907, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2006037994A2 (en) 2006-04-13
TW200617396A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2005056606A3 (en) Optimized antibodies that target the epidermal growth factor receptor
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2003085095A3 (en) Novel expressed genes
WO2004074455A3 (en) Fc REGION VARIANTS
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
BRPI0506771A (en) antibody and pharmaceutical composition
WO2007070280A3 (en) Use of deletion polymorphisms to predict, prevent, and manage histoincompatibility
WO2006081311A3 (en) Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors
EA201590833A1 (en) ANTIBODIES FOR THE TREATMENT AND PREVENTION OF THE ALZGEIMER'S DISEASE AND THEIR APPLICATION
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
NZ574046A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2008088893A3 (en) Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
WO2003013533A3 (en) Methods for improved treatment of cancer with irinotecan based on mrp1
BRPI0819018A2 (en) "methods to determine if a patient is at increased risk for developing hypertension, to determine if a patient is more likely to benefit from treatment with a vegf antagonist, and kits to determine if a patient is at increased risk of developing hypertension and to determine if a patient is more likely to benefit from treatment with a vegf antagonist "
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2009087462A3 (en) Ephrin type-a receptor 10 protein
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2008008983A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
WO2006037994A3 (en) Egfr mutations altering the response to erbb receptor drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase